Bohuichuangxin (300318.SZ) subsidiary obtains approval for clinical trials of intravenous human immunoglobulin

China Finance and Economics APP News, Bo Hui Innovation (300318.SZ) announced that its holding subsidiary Guangdong Weilun Biopharmaceutical Co., Ltd. (referred to as "Guangdong Weilun") has obtained the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for the intravenous human immunoglobulin it applied for, and has been approved to conduct clinical trials.